Literature DB >> 22678012

Long-term ingestion of Hibiscus sabdariffa calyx extract enhances myocardial capillarization in the spontaneously hypertensive rat.

Ibrahim Inuwa1, Badreldin H Ali, Intisar Al-Lawati, Sumaya Beegam, Amal Ziada, Gerald Blunden.   

Abstract

The effects of Hibiscus sabdariffa (HS) in lowering blood pressure in human and animal hypertension have been documented. This study investigated the effect of the water extract of the dried calyx of HS and Hibiscus anthocyanins (HAs) on left ventricular myocardial capillary length and surface area in spontaneously hypertensive rats (SHRs). Twelve-week-old male SHRs were divided into eight groups (six rats in each group). Three groups were given three doses; 10%, 15% and 20% of the water extract of HS in lieu of drinking water for 10 consecutive weeks (HS10, HS15 and HS20) with one group kept as control (C). Another three groups were given three doses of the HAs orally at doses of 50, 100 and 200 mg/kg for five consecutive days with one group kept as a control (C). Systolic (SBP) and diastolic (DBP) blood pressures, as well as heart rate (HR), were measured weekly. After the experimental protocols, the left ventricles (LV) of all rats were obtained. Capillary surface area density and length density were determined by unbiased sterological methods on 3 μm LV tissue samples from perfusion-fixed hearts. HS ingestion significantly reduced SBP, DBP and LV mass in a dose-dependent fashion but did not affect the HR. HS significantly increased surface area and length density of myocardial capillaries by 59%, 65% and 86%, and length density by 57%, 77% and 57%, respectively. Myocyte nuclear volume was significantly decreased in HS-treated rats. There was a decrease (although insignificant) in SBP and DBP with HA ingestion compared with controls. These changes suggest that the observed beneficial effect of HS on high BP in SHRs could be mediated through a reduction in the diffusion distance between capillaries and myocytes, as well as new vessel formation. It is proposed that these effects might be beneficial in restoring myocyte normal nutritional status compromised by the hypertrophic state of hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22678012     DOI: 10.1258/ebm.2012.011357

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  7 in total

Review 1.  Herbs Used for the Treatment of Hypertension and their Mechanism of Action.

Authors:  Steven G Chrysant; George S Chrysant
Journal:  Curr Hypertens Rep       Date:  2017-09-18       Impact factor: 5.369

Review 2.  Hibiscus sabdariffa L. in the treatment of hypertension and hyperlipidemia: a comprehensive review of animal and human studies.

Authors:  Allison L Hopkins; Marnie G Lamm; Janet L Funk; Cheryl Ritenbaugh
Journal:  Fitoterapia       Date:  2013-01-17       Impact factor: 2.882

Review 3.  Chinese Herbal Medicine on Cardiovascular Diseases and the Mechanisms of Action.

Authors:  Cuiqing Liu; Yu Huang
Journal:  Front Pharmacol       Date:  2016-12-01       Impact factor: 5.810

4.  Optimization of an Extraction Solvent for Angiotensin-Converting Enzyme Inhibitors from Hibiscus sabdariffa L. Based on Its UPLC-MS/MS Metabolic Profiling.

Authors:  Mohamed A Salem; Haidy E Michel; Marwa I Ezzat; Mona M Okba; Ahmed M El-Desoky; Shanaz O Mohamed; Shahira M Ezzat
Journal:  Molecules       Date:  2020-05-14       Impact factor: 4.411

5.  Roselle attenuates cardiac hypertrophy after myocardial infarction in vivo and in vitro.

Authors:  Lislivia-Yiang-Nee Si; Anand Ramalingam; Shafreena Shaukat Ali; Amnani Aminuddin; Pei-Yuen Ng; Jalifah Latip; Yusof Kamisah; Siti Balkis Budin; Satirah Zainalabidin
Journal:  EXCLI J       Date:  2019-09-26       Impact factor: 4.068

Review 6.  Anti-hypertensive Herbs and their Mechanisms of Action: Part I.

Authors:  Sara S Al Disi; M Akhtar Anwar; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-01-19       Impact factor: 5.810

Review 7.  Herbal Drugs from Sudan: Traditional Uses and Phytoconstituents.

Authors:  Mohamed Gamaleldin Elsadig Karar; Nikolai Kuhnert
Journal:  Pharmacogn Rev       Date:  2017 Jul-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.